Peter J Snyder

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7446758/publications.pdf

Version: 2024-02-01

		41344	14759
169	17,437	49	127
papers	citations	h-index	g-index
176	176	176	10220
176	176	176	19320
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
2	A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimer's Disease: Towards a More Continuous Approach. Journal of Alzheimer's Disease, 2022, 86, 511-524.	2.6	5
3	Retinal imaging in Alzheimer's and neurodegenerative diseases. Alzheimer's and Dementia, 2021, 17 , $103\text{-}111$.	0.8	89
4	Alzheimer's team care approach—akin to diabetes—in the development, validation, and population assessment of retinal biomarkers for disease. Alzheimer's and Dementia, 2021, 17, 112-114.	0.8	0
5	The relationship between cerebral and retinal microbleeds in cerebral amyloid angiopathy (CAA): A pilot study. Journal of the Neurological Sciences, 2021, 423, 117383.	0.6	6
6	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nature Medicine, 2021, 27, 1187-1196.	30.7	182
7	OCTA reveals remodeling of the peripheral capillary free zones in normal aging. Scientific Reports, 2021, 11, 15593.	3.3	4
8	A recommended "minimum data set―framework for SDâ€OCT retinal image acquisition and analysis from the Atlas of Retinal Imaging in Alzheimer's Study (ARIAS). Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12119.	2.4	3
9	Disruption of cholinergic neurotransmission, within a cognitive challenge paradigm, is indicative of Aβ-related cognitive impairment in preclinical Alzheimer's disease after a 27-month delay interval. Alzheimer's Research and Therapy, 2020, 12, 31.	6.2	6
10	Developing retinal biomarkers for the earliest stages of Alzheimer's disease: What we know, what we don't, and how to move forward. Alzheimer's and Dementia, 2020, 16, 229-243.	0.8	92
11	Retinal imaging think tank convened by the Alzheimer's Association to examine its promise in the early detection of Alzheimer's., 2020, 16, 244-244.		4
12	Rates of age―and amyloid βâ€essociated cortical atrophy in older adults with superior memory performance. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 566-575.	2.4	21
13	Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 2019, 41, 591-600.	1.3	18
14	Bloodâ€based biomarkers for Alzheimer's disease and related dementias: Keys to success and things to consider. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 784-786.	2.4	1
15	A Potential Association Between Retinal Changes, Subjective Memory Impairment, and Anxiety in Older Adults at Risk for Alzheimer's Disease: A 27-Month Pilot Study. Frontiers in Aging Neuroscience, 2019, 11, 288.	3.4	7
16	Change in retinal structural anatomy during the preclinical stage of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 196-209.	2.4	71
17	P3â€321: RETINAL NERVE FIBER LAYER THINNING AND SUBJECTIVE MEMORY IMPAIRMENT CHANGES IN PRECLINICAL ALZHEIMER'S DISEASE PATIENTS. Alzheimer's and Dementia, 2018, 14, P1204.	0.8	0
18	P1â€⊋92: RETINAL CHANGES IN CEREBRAL AMYLOID ANGIOPATHY (CAA): RELATIONSHIP TO CEREBRAL PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P398.	0.8	0

#	Article	IF	CITATIONS
19	P1â€132: DISRUPTION OF CHOLINERGIC NEUROTRANSMISSION, WITHIN A COGNITIVE CHALLENGE PARADIGM, PREDICTS Aβâ€RELATED COGNITIVE IMPAIRMENT IN PRECLINICAL ALZHEIMER'S DISEASE AFTER A 27â€MONTH DINTERVAL. Alzheimer's and Dementia, 2018, 14, P322.	DELAY	0
20	P1â€249: ALTERED MACULAR VASCULAR COMPLEXITY IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P374.	0.8	0
21	The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain, 2018, 141, 1917-1933.	7.6	1,008
22	Discontinuation and nonpublication of interventional clinical trials conducted in patients with mild cognitive impairment and Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 161-164.	3.7	17
23	Use of Eflornithine (DFMO) in the Treatment of Early Alzheimer's Disease: A Compassionate Use, Single-Case Study. Frontiers in Aging Neuroscience, 2018, 10, 60.	3.4	14
24	Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 65, 977-988.	2.6	15
25	Cognitive impairment and decline in cognitively normal older adults with high amyloidâ€Î²: A metaâ€analysis. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 108-121.	2.4	131
26	Brain amyloid in preclinical Alzheimer's disease is associated withÂincreased driving risk. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 136-142.	2.4	21
27	Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 7, 69-87.	2.4	283
28	Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 156-164.	2.4	19
29	Bloodâ€based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimer's and Dementia, 2017, 13, 45-58.	0.8	227
30	[P1–067]: USE OF EFLORNITHINE (DFMO) IN THE TREATMENT OF MILD ALZHEIMER'S DISEASE: A COMPASSIONATE USE SINGLE ASE STUDY. Alzheimer's and Dementia, 2017, 13, P263.	0.8	0
31	[P3â€"442]: CONTROLLED SEMANTIC RETRIEVAL IS SENSITIVE TO CHANGES IN BETAâ€AMYLOID LOAD IN PRECLINICAL ALZHEIMER's DISEASE: A NEUROCOGNITIVE STRESS TEST FOR ALZHEIMERâ€RELATED DISRUPTIONS TO FRONTOTEMPORAL PATHWAYS. Alzheimer's and Dementia, 2017, 13, P1138.	0.8	O
32	[P4–058]: RETINAL NERVE FIBER LAYER AND GANGLION CELL LAYER VOLUME CHANGES IN PRECLINICAL ALZHEIMER'S DISEASE OVER 27 MONTHS. Alzheimer's and Dementia, 2017, 13, P1280.	0.8	2
33	[P1–497]: AUDIOVISUAL SENSORY INTEGRATION IS SENSITIVE TO BETAâ€AMYLOID LOAD IN THE PRECLINICAL STAGE OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P481.	0.8	O
34	[P2–243]: A POTENTIAL RETINAL BIOMARKER OF CEREBRAL AMYLOID ANGIOPATHY. Alzheimer's and Dementia, 2017, 13, P704.	0.8	0
35	[O4–03–02]: CHOLINERGIC DEFICIT AS A PREDICTOR OF DISEASE PROGRESSION: AMYLOID ACCUMULATION AND EPISODIC MEMORY DECLINE IN A 27â€MONTH PRECLINICAL AD STUDY. Alzheimer's and Dementia, 2017, 13, P1232.	V 0.8	1
36	Autonomic Cardiac Function in Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 59, 1057-1065.	2.6	9

#	Article	IF	Citations
37	DADM: The first 2 years of the Alzheimer Association's open access journal to support the research and development of novel biomarkers and diagnostic approaches. Alzheimer's and Dementia, 2016, 12, 755-757.	0.8	O
38	P4â€144: Brain Amyloid in Preclinical Alzheimer's Disease is Associated with Increased Driving Risk. Alzheimer's and Dementia, 2016, 12, P1069.	0.8	1
39	AÎ ² -related memory decline in <i>APOE</i> Îμ4 noncarriers. Neurology, 2016, 86, 1635-1642.	1.1	37
40	Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia. Journal of Molecular Neuroscience, 2016, 60, 362-370.	2.3	14
41	Nonvascular retinal imaging markers of preclinical Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 169-178.	2.4	82
42	<i>BDNF</i> Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. Brain, 2016, 139, 2766-2777.	7.6	70
43	Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Zâ€scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 19-26.	2.4	72
44	A survey of knowledge and views concerning genetic and amyloid positron emission tomography status disclosure. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 23-29.	3.7	35
45	Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability. Alzheimer's and Dementia, 2016, 12, 454-458.	0.8	55
46	P4-120: PET amyloid binding in the anterior cingulate is related to incipient episodic memory changes in preclinical Alzheimer's disease., 2015, 11, P824-P824.		0
47	P2-194: Potential use of cogstate battery to monitor adverse events in individuals taking part in clinical trials of anti-amyloid drugs., 2015, 11, P567-P567.		0
48	O1-12-01: High-resolution retinal imaging in the identification of preclinical Alzheimer's disease. , 2015, 11, P158-P159.		0
49	P4-144: A survey of knowledge, beliefs, and attitudes regarding genetic and amyloid PET status disclosure. , 2015, 11, P834-P834.		0
50	P2-065: Resting-state cardiac workload increases in pre-clinical Alzheimer's disease., 2015, 11, P507-P508.		0
51	Human Language: Evolutionary Precursors. , 2015, , 329-334.		1
52	Introducing Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, an open access journal of the Alzheimer's Association. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 1-4.	2.4	6
53	P3-194: An ecologically valid measure of instrumental activities of daily living for preclinical Alzheimer's disease., 2015, 11, P706-P707.		0
54	O1-03-02: Disruption of cholinergic neurotransmission unmasks aß-related cognitive impairment in preclinical Alzheimer's disease., 2015, 11, P129-P130.		1

#	Article	IF	CITATIONS
55	O2-02-01: $\hat{Al^2}$ -related memory decline in preclinical Alzheimer's disease is delayed in ApoE-É>4 non-carriers. , 2015, 11, P174-P175.		О
56	APOE $\hat{l}\mu4$ moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1239-1244.	3.1	75
57	Relationships Between Performance on the Cogstate Brief Battery, Neurodegeneration, and AÂ Accumulation in Cognitively Normal Older Adults and Adults with MCI. Archives of Clinical Neuropsychology, 2015, 30, 49-58.	0.5	40
58	Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 103-111.	2.4	191
59	Disruption of cholinergic neurotransmission exacerbates $\hat{Al^2}$ -related cognitive impairment in preclinical Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2709-2715.	3.1	59
60	The Development of Associate Learning in School Age Children. PLoS ONE, 2014, 9, e101750.	2.5	7
61	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. , 2014, 10, S430-S452.		64
62	Behavior at the Choice Point: Decision Making in Hidden Pathway Maze Learning. Neuropsychology Review, 2014, 24, 514-536.	4.9	9
63	Microdosing of scopolamine as a "cognitive stress test†Rationale and test of a very low dose in an atâ€risk cohort of older adults. Alzheimer's and Dementia, 2014, 10, 262-267.	0.8	27
64	Effects of Testosterone and Growth Hormone on the Structural and Mechanical Properties of Bone by Micro-MRI in the Distal Tibia of Men With Hypopituitarism. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1236-1244.	3.6	29
65	Assessing cognition and function in Alzheimer's disease clinical trials: Do we have the right tools?. Alzheimer's and Dementia, 2014, 10, 853-860.	0.8	73
66	Amyloid-Î ² Related Memory Decline is not Associated with Subjective or Informant Rated Cognitive Impairment in Healthy Adults. Journal of Alzheimer's Disease, 2014, 43, 677-686.	2.6	63
67	Effect of cholinergic neurotransmission modulation on visual spatial paired associate learning in healthy human adults. Psychopharmacology, 2013, 228, 673-683.	3.1	15
68	Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. BMC Psychology, 2013, 1, 30.	2.1	153
69	The retooling of old cognitive tests as an interim step on the path to validating a next generation of neuropsychological paradigms and assays. Alzheimer's and Dementia, 2013, 9, S1-3.	0.8	5
70	Massed versus spaced visuospatial memory in cognitively healthy young and older adults. , 2013, 9, S32-S38.		8
71	BDNF Val66Met, $\hat{Al^2}$ amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2457-2464.	3.1	109
72	Neurologic Heuristics and Artistic Whimsy: The Cerebral Cartography Of Wilder Penfield. Journal of the History of the Neurosciences, 2013, 22, 277-291.	0.9	33

#	Article	IF	Citations
73	Measuring Executive Dysfunction Longitudinally and in Relation to Genetic Burden, Brain Volumetrics, and Depression in Prodromal Huntington Disease. Archives of Clinical Neuropsychology, 2013, 28, 156-168.	0.5	22
74	Short term stability of verbal memory impairment in mild cognitive impairment and Alzheimer's disease measured using the International Shopping List Test. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 853-863.	1.3	13
75	Preliminary Data on the Effect of Culture on the Assessment of Alzheimer's Disease-Related Verbal Memory Impairment with the International Shopping List Test. Archives of Clinical Neuropsychology, 2012, 27, 136-147.	0.5	14
76	A processâ€based approach to characterizing the effect of acute alprazolam challenge on visual paired associate learning and memory in healthy older adults. Human Psychopharmacology, 2012, 27, 549-558.	1.5	9
77	Editorial to accompany – Training the brain: Fact and fad in cognitive and behavioral remediation. Brain and Cognition, 2012, 79, 158.	1.8	1
78	Autonomic regulation and maze-learning performance in older and younger adults. Biological Psychology, 2011, 88, 20-27.	2.2	10
79	Biological markers of cognition in prodromal Huntington's disease: A review. Brain and Cognition, 2011, 77, 280-291.	1.8	42
80	Reliability, Stability, and Sensitivity to Change and Impairment in Acoustic Measures of Timing and Frequency. Journal of Voice, 2011, 25, 137-149.	1.5	58
81	Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010. , 2011, 7, 127-132.		35
82	The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 270-279.	0.8	7,498
83	Assessment of cognition in mild cognitive impairment: A comparative study. Alzheimer's and Dementia, 2011, 7, 338-355.	0.8	85
84	Assessment of cognition in early dementia. Alzheimer's and Dementia, 2011, 7, e60-e76.	0.8	75
85	Detecting Subtle Changes in Visuospatial Executive Function and Learning in the Amnestic Variant of Mild Cognitive Impairment. PLoS ONE, 2011, 6, e21688.	2.5	20
86	The Effects of Serum Calcium and Parathyroid Hormone Changes on Psychological and Cognitive Function in Patients Undergoing Parathyroidectomy for Primary Hyperparathyroidism. Annals of Surgery, 2011, 253, 131-137.	4.2	92
87	Baseline Burnout Symptoms Predict Visuospatial Executive Function During Survival School Training in Special Operations Military Personnel. Journal of the International Neuropsychological Society, 2011, 17, 494-501.	1.8	16
88	Examining the nature of impairment in visual paired associate learning in amnestic mild cognitive impairment Neuropsychology, 2011, 25, 752-762.	1.3	25
89	Sensitivity and Test-Retest Reliability of the International Shopping List Test in Assessing Verbal Learning and Memory in Mild Alzheimer's Disease. Archives of Clinical Neuropsychology, 2011, 26, 412-424.	0.5	39
90	Understanding failure of visual paired associate learning in amnestic mild cognitive impairment. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 1069-1078.	1.3	13

#	Article	IF	CITATIONS
91	Perception of alcohol intoxication shows acute tolerance while executive functions remain impaired Experimental and Clinical Psychopharmacology, 2010, 18, 329-339.	1.8	44
92	Use of an acute challenge with dâ€amphetamine to model cognitive improvement in chronic schizophrenia. Human Psychopharmacology, 2010, 25, 353-358.	1.5	39
93	A comparison of statistical approaches used to evaluate change in cognitive function following pharmacologic challenge: an example with lorazepam. Human Psychopharmacology, 2010, 25, 335-341.	1.5	10
94	Contagious Yawning in Autistic and Typical Development. Child Development, 2010, 81, 1620-1631.	3.0	72
95	Charles Darwin's Emotional Expression "Experiment―and His Contribution to Modern Neuropharmacology. Journal of the History of the Neurosciences, 2010, 19, 158-170.	0.9	9
96	Low Testosterone Must Explain Diminished Physical Performance in the Elderlyâ€"Right?. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2634-2635.	3.6	3
97	Amphetamine-related improvement in executive function in patients with chronic schizophrenia is modulated by practice effects. Schizophrenia Research, 2010, 124, 176-182.	2.0	23
98	Commentary on "Developing a national strategy to prevent dementia: Leon Thal Symposium 2009.―The rationale for a National Institutional Review Board for neurodegenerative diseases. , 2010, 6, 135-137.		2
99	Convergent Validity and Sex Differences in Healthy Elderly Adults for Performance on 3D Virtual Reality Navigation Learning and 2D Hidden Maze Tasks. Cyberpsychology, Behavior and Social Networking, 2009, 12, 169-174.	2.2	20
100	A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. Journal of Clinical and Experimental Neuropsychology, 2009, 31, 848-859.	1.3	156
101	Convergent Validity and Effect of Instruction Modification on the Groton Maze Learning Test: A New Measure of Spatial Working Memory and Error Monitoring. International Journal of Neuroscience, 2009, 119, 1137-1149.	1.6	16
102	Stability of cognitive impairment in chronic schizophrenia over brief and intermediate reâ€test intervals. Human Psychopharmacology, 2009, 24, 113-121.	1.5	40
103	Methodological improvements in quantifying cognitive change in clinical trials: An example with single-dose administration of donepezil. Journal of Nutrition, Health and Aging, 2009, 13, 268-273.	3.3	18
104	Standardization of pitch-range settings in voice acoustic analysis. Behavior Research Methods, 2009, 41, 318-324.	4.0	53
105	A method for cross-cultural adaptation of a verbal memory assessment. Behavior Research Methods, 2009, 41, 1190-1200.	4.0	60
106	Hunger and the perception of the scent of petrol: A potential neurobiological basis for increased risk of petrol inhalation abuse. Addiction Research and Theory, 2009, 17, 518-524.	1.9	2
107	Immediate and delayed effects of cognitive interventions in healthy elderly: A review of current literature and future directions. Alzheimer's and Dementia, 2009, 5, 50-60.	0.8	215
108	Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.―Recruitment of participants for Alzheimer's disease clinical trials: The role of trust in caregivers, clinical researchers, regulatory authorities, and industry sponsor. , 2009, 5, 122-124.		10

#	Article	IF	Citations
109	A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimer's and Dementia, 2009, 5, 85-92.	0.8	44
110	Double-Blind Crossover Study of the Cognitive Effects of Lorazepam in Healthy Apolipoprotein E (<i>APOE</i>)-ε4 Carriers. Journal of Clinical Psychiatry, 2009, 70, 1379-1384.	2.2	23
111	The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine. Human Psychopharmacology, 2008, 23, 425-436.	1.5	58
112	Aging and electrocortical response to error feedback during a spatial learning task. Psychophysiology, 2008, 45, 936-948.	2.4	45
113	Trait impulsiveness and executive function in healthy young adults. Journal of Research in Personality, 2008, 42, 1347-1351.	1.7	32
114	Specific impairments in visuospatial working and short-term memory following low-dose scopolamine challenge in healthy older adults. Neuropsychologia, 2008, 46, 2476-2484.	1.6	48
115	An examination of the construct validity and factor structure of the Groton Maze Learning Test, a new measure of spatial working memory, learning efficiency, and error monitoring. Archives of Clinical Neuropsychology, 2008, 23, 433-445.	0.5	82
116	Spatial working memory and problem solving in schizophrenia: The effect of symptom stabilization with atypical antipsychotic medication. Psychiatry Research, 2008, 160, 316-326.	3.3	34
117	A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium. Alzheimer's and Dementia, 2008, 4, 156-163.	0.8	42
118	Effect of Treatment with Stimulant Medication on Nonverbal Executive Function and Visuomotor Speed in Children with Attention Deficit/Hyperactivity Disorder (ADHD). Child Neuropsychology, 2008, 14, 211-226.	1.3	41
119	Androgens. , 2008, , 1783-1792.		1
120	Visuospatial Working Memory in School-aged Children Exposed <i>In Utero</i> to Cocaine. Child Neuropsychology, 2007, 13, 205-218.	1.3	46
121	Spatial learning efficiency and error monitoring in normal aging: An investigation using a novel hidden maze learning test. Archives of Clinical Neuropsychology, 2007, 22, 235-245.	0.5	42
122	Cognitive testing in early-phase clinical trials: Development of a rapid computerized test battery and application in a simulated Phase I study. Contemporary Clinical Trials, 2007, 28, 391-400.	1.8	73
123	Voice acoustic measures of depression severity and treatment response collected via interactive voice response (IVR) technology. Journal of Neurolinguistics, 2007, 20, 50-64.	1.1	261
124	Historical note on Darwin's consideration of early-onset dementia in older persons, thirty-six years before Alzheimer's initial case report., 2007, 3, 137-142.		7
125	Effect of Growth Hormone Replacement on BMD in Adult-Onset Growth Hormone Deficiency. Journal of Bone and Mineral Research, 2007, 22, 762-770.	2.8	39
126	Does atypical antipsychotic medication improve executive function in schizophrenia?. International Journal of Neuropsychopharmacology, 2006, 9, 629.	2.1	1

#	Article	IF	CITATIONS
127	A statistical approach for classifying change in cognitive function in individuals following pharmacologic challenge: an example with alprazolam. Psychopharmacology, 2006, 186, 7-17.	3.1	38
128	Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Neuroscience and Biobehavioral Reviews, 2006, 30, 1225-1245.	6.1	193
129	Cognitive testing in early phase clinical trials: outcome according to adverse event profile in a Phase I study. Human Psychopharmacology, 2006, 21, 481-488.	1.5	21
130	Bradyphrenia and Bradykinesia Both Contribute to Altered Speech in Schizophrenia. Cognitive and Behavioral Neurology, 2005, 18, 206-210.	0.9	23
131	Effect of Testosterone Replacement on Trabecular Architecture in Hypogonadal Men. Journal of Bone and Mineral Research, 2005, 20, 1785-1791.	2.8	171
132	Parathyroidectomy improves neurocognitive deficits in patients with primary hyperparathyroidism. Surgery, 2005, 138, 1121-1129.	1.9	109
133	A method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses alprazolam. Human Psychopharmacology, 2005, 20, 263-273.	1.5	99
134	Remote capture of human voice acoustical data by telephone: A methods study. Clinical Linguistics and Phonetics, 2005, 19, 649-658.	0.9	15
135	Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor., 2005, 1, 126-135.		112
136	Proteomic Approaches in Drug Discovery and Development. International Review of Neurobiology, 2004, 61, 97-126.	2.0	8
137	Speech Content Analysis in Feigned Depression. Journal of Psycholinguistic Research, 2004, 33, 289-301.	1.3	5
138	Development and Validation of an LC/MS/MS Procedure for the Quantification of Endogenousmyo-Inositol Concentrations in Rat Brain Tissue Homogenates. Analytical Chemistry, 2004, 76, 4901-4908.	6.5	40
139	Feigned depression and feigned sleepiness: A voice acoustical analysis. Brain and Cognition, 2004, 55, 383-386.	1.8	6
140	Impaired performance of children exposed in utero to cocaine on a novel test of visuospatial working memory. Brain and Cognition, 2004, 55, 409-412.	1.8	54
141	Variability in fundamental frequency during speech in prodromal and incipient Parkinson's disease: A longitudinal case study. Brain and Cognition, 2004, 56, 24-29.	1.8	202
142	Voice acoustical measurement of the severity of major depression. Brain and Cognition, 2004, 56, 30-35.	1.8	157
143	Acoustic characteristics of Parkinsonian speech: a potential biomarker of early disease progression and treatment. Journal of Neurolinguistics, 2004, 17, 439-453.	1.1	123
144	Reversed cerebellar asymmetry in men with First-Episode schizophrenia. Biological Psychiatry, 2003, 53, 450-459.	1.3	42

#	Article	IF	CITATIONS
145	Lack of Normal Association Between Cerebellar Volume and Neuropsychological Functions in First-Episode Schizophrenia. American Journal of Psychiatry, 2003, 160, 1884-1887.	7.2	41
146	Deterioration of Trabecular Architecture in Hypogonadal Men. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1497-1502.	3.6	152
147	Postnatal development of lateralized motor preference in the African Grey parrot (Psittacus) Tj ETQq1 1 0.784314	1 rgBT /Ov 1:8	erjock 10 Tf
148	Information processing speed deficits may be better correlated with the extent of white matter sclerotic lesions in multiple sclerosis than previously suspected. Brain and Cognition, 2001, 46, 279-284.	1.8	34
149	Improved detection of differential information-processing speed deficits between two disease-course types of multiple sclerosis Neuropsychology, 2001, 15, 617-625.	1.3	35
150	Epilepsia Verminosa*. Journal of the History of the Neurosciences, 2001, 10, 163-172.	0.9	4
151	GABA levels within the medial preoptic area: effects of chronic administration of sodium valproic acid. Psychoneuroendocrinology, 2000, 25, 519-534.	2.7	13
152	Sodium valproate alters GnRH–GABA interactions during development in seizure-prone mice. Brain Research, 2000, 885, 192-200.	2.2	14
153	Effects of Testosterone Replacement in Hypogonadal Men ¹ . Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2670-2677.	3.6	497
154	Long-Term Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men ¹ . Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4500-4510.	3.6	287
155	Darwin's Contribution to Neuropsychology in the Twenty-First Century. Brain and Cognition, 2000, 42, 41-43.	1.8	1
156	Generalizability of Aphasiology Studies: Nontraditional Populations Examined. Brain and Language, 2000, 71, 344-349.	1.6	0
157	Evolutionary Bases for Cerebral Localization of Higher Cognitive Functions. Brain and Language, 2000, 73, 127-131.	1.6	1
158	Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age ¹ . Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1966-1972.	3.6	505
159	The Evolution of Communication: An Ethological Exploration. Brain and Language, 1998, 62, 465-468.	1.6	1
160	Cerebral Hemispheric Control of Speech during the Intracarotid Sodium Amytal Procedure: An Acoustic Exploration. Brain and Language, 1997, 60, 243-254.	1.6	2
161	Lexicon size and its relation to foot preference in the African Grey parrot (Psittacus erithacus). Neuropsychologia, 1997, 35, 919-926.	1.6	49
162	Chronic administration of sodium valproic acid slows pubertal maturation in inbred DBA/2J mice: Skeletal, histological, and endocrinological evidence. Epilepsy Research, 1995, 20, 203-211.	1.6	48

PETER J SNYDER

#	Article	IF	CITATION
163	Personality and lipid level differences associated with homosexual and bisexual identity in men. Archives of Sexual Behavior, 1994, 23, 433-451.	1.9	12
164	A factor analysis of the Klein sexual orientation Grid in two disparate samples. Archives of Sexual Behavior, 1993, 22, 157-168.	1.9	65
165	Mixed speech dominance in the intracarotid sodium amytal procedure: Validity and criteria issues. Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology, 1990, 12, 629-643.	1.1	71
166	The influence of estrous cycle and intrastriatal estradiol on sensorimotor performance in the female rat. Pharmacology Biochemistry and Behavior, 1987, 27, 53-59.	2.9	155
167	Endocrine, cardiovascular, and psychological correlates of olfactory sensitivity changes during the human menstrual cycle Journal of Comparative and Physiological Psychology, 1981, 95, 45-60.	1.8	217
168	Treatment of Male Hypogonadism with Testosterone Enanthate*. Journal of Clinical Endocrinology and Metabolism, 1980, 51, 1335-1339.	3.6	289
169	Avoid or Embrace? Practice Effects in Alzheimerâ \in Ms Disease Prevention Trials. Frontiers in Aging Neuroscience, 0, 14, .	3.4	3